141 related articles for article (PubMed ID: 15059880)
61. Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer.
Peng CL; Lin HC; Chiang WL; Shih YH; Chiang PF; Luo TY; Cheng CC; Shieh MJ
Photodiagnosis Photodyn Ther; 2018 Sep; 23():111-118. PubMed ID: 29894822
[TBL] [Abstract][Full Text] [Related]
62. Identification of MAP kinase pathways involved in COX-2 expression following photofrin photodynamic therapy.
Luna M; Ferrario A; Wong S; Gomer CJ
Methods Mol Biol; 2010; 635():47-63. PubMed ID: 20552339
[TBL] [Abstract][Full Text] [Related]
63. Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy.
Domagala A; Stachura J; Gabrysiak M; Muchowicz A; Zagozdzon R; Golab J; Firczuk M
BMC Cancer; 2018 Feb; 18(1):210. PubMed ID: 29463237
[TBL] [Abstract][Full Text] [Related]
64. Low-dose photodynamic therapy increases endothelial cell proliferation and VEGF expression in nude mice brain.
Zhang X; Jiang F; Zhang ZG; Kalkanis SN; Hong X; deCarvalho AC; Chen J; Yang H; Robin AM; Chopp M
Lasers Med Sci; 2005 Sep; 20(2):74-9. PubMed ID: 16096716
[TBL] [Abstract][Full Text] [Related]
65. Characterization of photodynamic therapy responses elicited in A431 cells containing intracellular organelle-localized photofrin.
Hsieh YJ; Yu JS; Lyu PC
J Cell Biochem; 2010 Nov; 111(4):821-33. PubMed ID: 20665537
[TBL] [Abstract][Full Text] [Related]
66. Photodynamic activity of lutetium-texaphyrin in a mouse tumor system.
Hammer-Wilson MJ; Ghahramanlou M; Berns MW
Lasers Surg Med; 1999; 24(4):276-84. PubMed ID: 10327046
[TBL] [Abstract][Full Text] [Related]
67. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy.
Korbelik M; Krosl G; Krosl J; Dougherty GJ
Cancer Res; 1996 Dec; 56(24):5647-52. PubMed ID: 8971170
[TBL] [Abstract][Full Text] [Related]
68. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry.
Butler GS; Overall CM
Curr Pharm Des; 2007; 13(3):263-70. PubMed ID: 17313360
[TBL] [Abstract][Full Text] [Related]
69. Glucose administration combined with photodynamic therapy of cancer improves therapeutic efficacy.
Nelson JS; Kimel S; Brown L; Berns MW
Lasers Surg Med; 1992; 12(2):153-8. PubMed ID: 1573965
[TBL] [Abstract][Full Text] [Related]
70. Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter.
Luna MC; Chen X; Wong S; Tsui J; Rucker N; Lee AS; Gomer CJ
Cancer Res; 2002 Mar; 62(5):1458-61. PubMed ID: 11888920
[TBL] [Abstract][Full Text] [Related]
71. Effects of photodynamic therapy on adhesion molecules and metastasis.
Rousset N; Vonarx V; Eléouet S; Carré J; Kerninon E; Lajat Y; Patrice T
J Photochem Photobiol B; 1999; 52(1-3):65-73. PubMed ID: 10643074
[TBL] [Abstract][Full Text] [Related]
72. In vivo resistance to photofrin-mediated photodynamic therapy in radiation-induced fibrosarcoma cells resistant to in vitro Photofrin-mediated photodynamic therapy.
Adams K; Rainbow AJ; Wilson BC; Singh G
J Photochem Photobiol B; 1999 Apr; 49(2-3):136-41. PubMed ID: 10392463
[TBL] [Abstract][Full Text] [Related]
73. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
[TBL] [Abstract][Full Text] [Related]
74. Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice.
Akgül B; Pfefferle R; Marcuzzi GP; Zigrino P; Krieg T; Pfister H; Mauch C
Exp Dermatol; 2006 Jan; 15(1):35-42. PubMed ID: 16364029
[TBL] [Abstract][Full Text] [Related]
75. The role of the p53 tumor suppressor in the response of human cells to photofrin-mediated photodynamic therapy.
Tong Z; Singh G; Rainbow AJ
Photochem Photobiol; 2000 Feb; 71(2):201-10. PubMed ID: 10687395
[TBL] [Abstract][Full Text] [Related]
76. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.
Wang HW; Putt ME; Emanuele MJ; Shin DB; Glatstein E; Yodh AG; Busch TM
Cancer Res; 2004 Oct; 64(20):7553-61. PubMed ID: 15492282
[TBL] [Abstract][Full Text] [Related]
77. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.
Tatar O; Adam A; Shinoda K; Eckert T; Scharioth GB; Klein M; Yoeruek E; Bartz-Schmidt KU; Grisanti S
Br J Ophthalmol; 2007 Sep; 91(9):1183-9. PubMed ID: 17475706
[TBL] [Abstract][Full Text] [Related]
78. The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy.
Korbelik M; Naraparaju VR; Yamamoto N
Br J Cancer; 1998 Mar; 77(6):1009-14. PubMed ID: 9528849
[TBL] [Abstract][Full Text] [Related]
79. Molecular changes following topical photodynamic therapy using methyl aminolaevulinate in mouse skin.
Choi JY; Park GT; Na EY; Wi HS; Lee SC; Lee JB
J Dermatol Sci; 2010 Jun; 58(3):198-203. PubMed ID: 20434314
[TBL] [Abstract][Full Text] [Related]
80. Increased expression of matrix metalloproteinases mediates thromboxane A2-induced invasion in lung cancer cells.
Li X; Tai HH
Curr Cancer Drug Targets; 2012 Jul; 12(6):703-15. PubMed ID: 22515524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
